4[1]Roth BJ, Johnson DH, Einhorn LH, et al. Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase Ⅲ trial of Southeastern Cancer Study Group [J]. J Clin Oncol, 1992, 10(2): 282-291.
5[2]Fukuoka M, Furuse K,Saijo N,et al. Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer [J]. J Natl Cancer Inst,1991,83(12): 855-861.
6[3]Shepherd FA, Evans WK, MacCormick R, et al. Cyclophosphamide, doxorubicin, and vincristine in etoposide and cisplatin-resistant small cell lung cancer [J]. Cancer Treat Rep, 1987, 71(10): 941-944.
7[4]Ardizzoni A, Hansen H, Dombernowsky P, et al. Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: A phase II study in patients with refractory and sensitive disease [J]. J Clin Oncol, 1997, 15(5): 2090-2096.
8[5]Von-Pawel J, Schiller JH, Shepherd FA, et al. Topotecan versus cyclophosphamide, doxorubicin,and vincristine for treatment of recurrent small cell lung cancer [J]. J Clin Oncol, 1999, 17(2): 658-667.
9[6]Perez-Soler R, Glisson BS, Lee JS, et al. Treatment of patients with small-cell lung cancer refractory to etoposide and cisplatin with the topoisomerase I poison topotecan [J]. J Clin Oncol, 1996, 14(10): 2785-2790.
